contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


change-in-the-revenio-leadership-team-kate-taylor-to-step-down

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand.

In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

De er sandsynligvis en reaktion på kursen. Revenios kursmål har altid fulgt kursen mere bagudrettet end den faktiske markedssituation. Intet har reelt ændret sig, og nu hvor den interne situation i USA begynder at blive mere klar, vil markedssituationen kun forbedres. Dette var optimisme, det er der brug for i verden nu.

Mon jeg er på rette spor med, at de faldende kursmål i høj grad skyldes svækkelsen af dollarkursen? For 12 måneder siden var EUR/USD på 1,04 og nu 1,18. Selvom handlen i USA går godt, er det hjemtagne afkast på vej til at skrumpe. Gad vide hvilket andet markedsområde der realistisk set (i det mindste i nogen grad) kunne opveje effekten af denne udvikling.

iCare – 15 Jan 26              iCare, epitop, and bon Optic Forge Strategic Alliance to Transform Screening...    First milestone: iCare Screening Solution integrated into epitop VISION         Estimated reading time: 3 minutes                               Revenio har et strategisk partnerskab med et tysk firma om RetCAD-screening. Jeg kan ikke vurdere, hvor betydelig en nyhed der er tale om.

Kunne dagens meddelelser læses sammen på denne måde; Kate Taylors Oculo-baserede arbejde er nu afsluttet, og den første end-to-end-behandlingsforløbsmodel er lanceret i Tyskland. For Taylors vedkommende slutter integrations- og strategiforløbet her efter forudgående aftale og i gensidig forståelse, og Revenio går videre til kommercialisering og skalering af modellen, forhåbentlig med stor succes.

Husker jeg rigtigt, at Robin Pulkkinen allerede har trukket stikket, og tilsyneladende kun er i ledelsen i en kort stund endnu? Man ville have forventet, at det var blevet nævnt i den meddelelse, så at sige for en god ordens skyld.

Jeg tager en yderst optimistisk tilgang til denne meddelelse og siger, at afgangen skyldes, at Reve nu har klare planer for, hvad de gør, og at der ikke er nogen opkøb i sigte. Jeg ved ikke, hvorfor alle i ledelsen har titlen Vice President. Har de ikke set American Psycho?

Revenio Group

Revenio Group Corporation | Stock Exchange Release | January 15, 2026 at 14:30:00 EETLeadership team member Dr. Kate Taylor (Vice President, Strategy and Business Development), will step down...

<div class="mfn-header mfn-header-finland">Revenio Group Corporation | Stock Exchange Release | January 15, 2026 at 14:30:00 EET</div><div class="mfn-body">Leadership team member Dr. Kate Taylor (Vice President, Strategy and Business Development), will step down from her position by January 31, 2026. She has been based in Australia. The responsibilities of Vice President, Strategy and Business Development will be shared by the CEO Jouni Toijala and the Leadership Team.“I would like to thank Kate for her significant contribution to advancing the Group’s strategy. Kate has played an important role in integrating Oculo, which she founded and which we acquired in 2021, into the Revenio Group. Her role has also been instrumental in building our software solutions business. I wish her every success in the future,” says Jouni Toijala, CEO of Revenio Group.As of February 1, 2026, the Leadership Team of Revenio Group will consist of:<ul><li>Jouni Toijala, CEO</li><li>John Floyd, Vice President, Sales</li><li>Heli Huopaniemi, Vice President, Quality</li><li>Ari Isomäki, Vice President, Operations</li><li>Robin Pulkkinen, CFO</li><li>Marco Rizzardo, Vice President, R&amp;D</li><li>Erkki Tala, Vice President, Products, Brand and Marketing</li><li>Hanna Vuornos, Vice President, People and Culture </li></ul>Further information CEO Jouni Toijala, tel. +358 50 484 0085 <a rel="noopener" href="mailto:jouni.toijala@revenio.fi">jouni.toijala@revenio.fi</a>Distribution Nasdaq Helsinki Financial Supervisory Authority (FIN-FSA) Key media <a rel="noopener" href="http://www.reveniogroup.fi/en">www.reveniogroup.fi/en</a>Revenio Group in brief Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand.In 2024, the Group’s net sales totaled EUR 103.5 million, with an operating profit of EUR 25.0 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="noopener" href="https://storage.mfn.se/81a29ed7-ffff-4a52-a5ad-6d80a586bb5c/change-in-the-revenio-leadership-team-kate-taylor-to-step-down.pdf" class="mfn-generated mfn-primary">Change in the Revenio Leadership Team: Kate Taylor to step down</a></div>